Phase II study of aflibercept in recurrent malignant glioma: A North American brain tumor consortium study Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Glioma
  • Recombinant Fusion Proteins

abstract

  • Aflibercept monotherapy has moderate toxicity and minimal evidence of single-agent activity in unselected patients with recurrent malignant glioma.

publication date

  • July 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3139373

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.34.1636

PubMed ID

  • 21606416

Additional Document Info

start page

  • 2689

end page

  • 95

volume

  • 29

number

  • 19